{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:50:02Z","timestamp":1794135002988,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002670","name":"ABB","doi-asserted-by":"publisher","award":["NCT 02081313"],"award-info":[{"award-number":["NCT 02081313"]}],"id":[{"id":"10.13039\/501100002670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["239"],"award-info":[{"award-number":["239"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["50373"],"award-info":[{"award-number":["50373"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jid.2021.01.029","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T22:53:05Z","timestamp":1616107985000},"page":"2272-2279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1805-3728","authenticated-orcid":false,"given":"John","family":"Liddle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-4992","authenticated-orcid":false,"given":"Veronique","family":"Beneton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-0439","authenticated-orcid":false,"given":"Matthew","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-224X","authenticated-orcid":false,"given":"Ryan","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-5714","authenticated-orcid":false,"given":"Anne","family":"Bouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1146-0526","authenticated-orcid":false,"given":"Anne-Benedicte","family":"Boullay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2909-6117","authenticated-orcid":false,"given":"Eloisa","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-6121","authenticated-orcid":false,"given":"Jenni","family":"Cryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-7517","authenticated-orcid":false,"given":"Alexis","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4202-8215","authenticated-orcid":false,"given":"Emma","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5968-7682","authenticated-orcid":false,"given":"Alan","family":"Ferrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0488-5403","authenticated-orcid":false,"given":"Marie-Helene","family":"Fouchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-6514","authenticated-orcid":false,"given":"Didier","family":"Grillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-8606","authenticated-orcid":false,"given":"Duncan S.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9707-2067","authenticated-orcid":false,"given":"Ashleigh","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-3521","authenticated-orcid":false,"given":"Gael","family":"Krysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-1691","authenticated-orcid":false,"given":"Alain","family":"Laroze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-3302","authenticated-orcid":false,"given":"Mark","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-5073","authenticated-orcid":false,"given":"Fiona","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9596","authenticated-orcid":false,"given":"Alexandre","family":"Moquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-7750","authenticated-orcid":false,"given":"Edwige","family":"Nicodeme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-878X","authenticated-orcid":false,"given":"Brandon","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-6047","authenticated-orcid":false,"given":"Leandro","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-2006","authenticated-orcid":false,"given":"Kathrine J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-4453","authenticated-orcid":false,"given":"James H.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0992-2269","authenticated-orcid":false,"given":"Gary","family":"Thripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-6806","authenticated-orcid":false,"given":"Lionel","family":"Trottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1027-2099","authenticated-orcid":false,"given":"Ann L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-1462","authenticated-orcid":false,"given":"Simon A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-2318","authenticated-orcid":false,"given":"Yichen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8768-7906","authenticated-orcid":false,"given":"Steve","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-037X","authenticated-orcid":false,"given":"Andrew C.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3412-7512","authenticated-orcid":false,"given":"Alain","family":"Hovnanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.01.029_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","article-title":"Successful use of secukinumab in Netherton syndrome","volume":"6","author":"Blanchard","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2021.01.029_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0169-328X(02)00417-5","article-title":"The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR","volume":"106","author":"Bond","year":"2002","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.jid.2021.01.029_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1172\/JCI41440","article-title":"Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing","volume":"120","author":"Bonnart","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.01.029_bib4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20082242","article-title":"Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome","volume":"206","author":"Briot","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2021.01.029_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/75977","article-title":"Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome","volume":"25","author":"Chavanas","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2021.01.029_bib6","article-title":"Tissue kallikrein inhibitors based on the sunflower trypsin inhibitor scaffold - a potential therapeutic intervention for skin diseases","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.01.029_bib7","article-title":"Potent, multi-target serine protease inhibition achieved by a simplified \u03b2-sheet motif","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.01.029_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jid.2016.09.017","article-title":"Selective substrates and inhibitors for kallikrein-related peptidase 7 (KLK7) shed light on KLK proteolytic activity in the stratum corneum","volume":"137","author":"de Veer","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/BJ20150412","article-title":"Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition","volume":"469","author":"de Veer","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.jid.2021.01.029_bib10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1515\/hsz-2016-0112","article-title":"Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors","volume":"397","author":"de Veer","year":"2016","journal-title":"Biol Chem"},{"key":"10.1016\/j.jid.2021.01.029_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jmb.2007.08.042","article-title":"Structural basis of the zinc inhibition of human tissue kallikrein 5","volume":"373","author":"Debela","year":"2007","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jid.2021.01.029_bib12","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1091\/mbc.e07-02-0124","article-title":"LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction","volume":"18","author":"Deraison","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jid.2021.01.029_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng1493","article-title":"Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity","volume":"37","author":"Descargues","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2021.01.029_bib14","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.jid.5700284","article-title":"Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome","volume":"126","author":"Descargues","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib15","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1515\/cclm-2019-0123","article-title":"Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses","volume":"57","author":"Di Paolo","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jid.2021.01.029_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/jid.1967.156","article-title":"Rate of turnover of the stratum corneum in hairless mice","volume":"49","author":"Downes","year":"1967","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib17","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/jid.2011.124","article-title":"Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin","volume":"131","author":"Fontao","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib18","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/jid.2011.174","article-title":"Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis","volume":"131","author":"Fortugno","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1084\/jem.20131797","article-title":"Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome","volume":"211","author":"Furio","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2021.01.029_bib20","article-title":"KLK5 inactivation reverses cutaneous hallmarks of netherton syndrome","volume":"21","author":"Furio","year":"2015","journal-title":"PLOS Genet"},{"key":"10.1016\/j.jid.2021.01.029_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2021.01.029_bib22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jid.2019.10.026","article-title":"Transgenic kallikrein 14 mice display major hair shaft defects associated with desmoglein 3 and 4 degradation, abnormal epidermal differentiation, and Il-36 signature","volume":"140","author":"Gouin","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.jid.5700288","article-title":"Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome","volume":"126","author":"Hachem","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/hmg\/ddi030","article-title":"Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome","volume":"14","author":"Hewett","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jid.2021.01.029_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/edm.11.85","article-title":"Netherton syndrome: new advances in the clinic, disease mechanism and treatment","volume":"7","author":"Hovnanian","year":"2012","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00441-013-1558-1","article-title":"Netherton syndrome: skin inflammation and allergy by loss of protease inhibition","volume":"351","author":"Hovnanian","year":"2013","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jid.2021.01.029_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006566","article-title":"KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype","volume":"13","author":"Kasparek","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jid.2021.01.029_bib28","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1515\/hsz-2016-0203","article-title":"Mechanistic insight from murine models of Netherton syndrome","volume":"397","author":"Keuylian","year":"2016","journal-title":"Biol Chem"},{"key":"10.1016\/j.jid.2021.01.029_bib29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab Therapy for Netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaci.2018.03.021","article-title":"Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature","volume":"143","author":"Malik","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.01.029_bib31","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2011.10338.x","article-title":"Influence of Aqueous Cream BP on corneocyte size, maturity, skin protease activity, protein content and transepidermal water loss","volume":"164","author":"Mohammed","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.01.029_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/21678707.2020.1857724","article-title":"Advances in understanding of Netherton syndrome and therapeutic implications","volume":"8","author":"Petrova","year":"2020","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.jid.2021.01.029_bib33","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Comel-Netherton syndrome defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.01.029_bib34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jdcr.2017.07.019","article-title":"Infliximab therapy for Netherton syndrome: a case report","volume":"3","author":"Roda","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2021.01.029_bib35","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of Netherton Syndrome With Dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib36","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1016\/j.bmcl.2013.06.039","article-title":"1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases","volume":"23","author":"Tan","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2021.01.029_bib37","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejmech.2013.10.040","article-title":"Identification by in silico and in\u00a0vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins","volume":"70","author":"Tan","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jid.2021.01.029_bib38","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1021\/jm500988d","article-title":"Toward the first class of suicide inhibitors of kallikreins involved in skin diseases","volume":"582","author":"Tan","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jid.2021.01.029_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1107\/S2053230X19003169","article-title":"Evaluation of a crystallographic surrogate for Kallikrein 5 in the discovery of novel inhibitors for Netherton Syndrome","volume":"75","author":"Thorpe","year":"2019","journal-title":"Acta Crystallogr F Struct Biol Commun"},{"key":"10.1016\/j.jid.2021.01.029_bib40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1194\/jlr.RA120000639","article-title":"Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities","volume":"61","author":"van Smeden","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jid.2021.01.029_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjd.18892","article-title":"Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl","volume":"183","author":"Volc","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.01.029_bib42","doi-asserted-by":"crossref","first-page":"126675","DOI":"10.1016\/j.bmcl.2019.126675","article-title":"Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors","volume":"29","author":"Walker","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2021.01.029_bib43","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bmcl.2019.04.022","article-title":"Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome","volume":"15","author":"Walker","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2021.01.029_bib44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bmcl.2019.01.020","article-title":"Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome","volume":"29","author":"White","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jid.2021.01.029_bib45","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1101\/gad.1232104","article-title":"Epidermal detachment, desmosomal dissociation, and destabilization of corneodesmosinin Spink5 -\/- mice","volume":"18","author":"Yang","year":"2004","journal-title":"Genes Dev"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21009945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21009945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:46:14Z","timestamp":1762206374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21009945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0022202X21009945"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.01.029","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}